Portal de Periódicos da CAPES

Management of graft-versus-host disease

1993; Wiley; Volume: 51; Issue: 1 Linguagem: Holandês

10.1111/j.1600-0609.1993.tb00597.x

1600-0609

Olle Ringdén,

T-cell and B-cell Immunology

European Journal of HaematologyVolume 51, Issue 1 p. 1-12 Free Access Management of graft-versus-host disease Olle Ringdén, Corresponding Author Olle Ringdén Departments of Clinical Immunology and Transplantation Surgery, Huddinge Hospital, Huddinge, SwedenDepartment of Clinical Immunology, Huddinge Hospital, S-141 86 Huddinge, Sweden. Phone: 087465710, Fax: 087466869Search for more papers by this author Olle Ringdén, Corresponding Author Olle Ringdén Departments of Clinical Immunology and Transplantation Surgery, Huddinge Hospital, Huddinge, SwedenDepartment of Clinical Immunology, Huddinge Hospital, S-141 86 Huddinge, Sweden. Phone: 087465710, Fax: 087466869Search for more papers by this author First published: July 1993 https://doi.org/10.1111/j.1600-0609.1993.tb00597.xCitations: 22AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Van Bekkum DW, De Vries JJ. Radiation Chimaeras. London: Logos, 1967: pp. 277. 2 Billingham RE. The biology of graft-versus-host reactions. Harvey Lectures 196667: 62: 21. 3 Renkonen R., Häyry P. Cellular infiltrates in the target organs associated with acute graft-versus-host disease. Bone Marrow Transplant 1987: 2: 333– 346. 4 Dicke KA, Tridente G., Van Bekkum DW. The selective elimination of immunologically competent cells from bone marrow and lymphocytic cell mixtures. III. In vitro test for detection of immunocompetent cells in fractionated mouse spleen cell suspensions and primate bone marrow suspensions. Transplantation 1969: 8: 422– 434. 5 Korngold R., Sprent J. T cell subsets and graft-versus-host disease. Transplantation 1987: 44: 335– 339. 6 Mitsuyasu RT, Champlin RE, Gale RP, et al. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. Ann Int Med 1986: 105: 20– 26. 7 Maraninchi D., Gluckman E., Blaise D., et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 1987: 2: 175– 178. 8 Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985: 313: 765– 771. 9 Ash RC, Horowitz MM, Gale RP, et al. Bone marrow transplantation from related donors other than HLA-identical siblings. Effect of T-cell depletion. Bone Marrow Transplant 1991: 7: 443– 452. 10 Beatty PG, Hansen JA, Longton GM, et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991: 51: 443– 447. 11 Thomas ED, Storb R., Clift RA, et al. Bone-marrow transplantation I and II. N Engl J Med 1975: 292: 832– 843, 895–902. 12 Sale GE, Shulman HM. The pathology of bone marrow transplantation. Masson Monographs in Diagnostic Pathology, 1984. 13 Paulin T., Ringdén O., Nilsson B. Immunological recovery after bone marrow transplantation: role of age, graft-versus-host disease, prednisolone treatment and infections. Bone Marrow Transplantation 1987: 1: 317– 328. 14 Meyers JD, Thomas ED. Infection complicating bone marrow transplantation. In: RH Rubin, LS Young, eds. Clinical approach to infection in the immunocompromised host. New York: Plenum Press, 1982: 507– 551. 15 Ringdén O., Nilsson B. Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy. Transplantation 1985: 40: 39– 44. 16 Storb R., Prentice RL, Thomas ED. Treatment of aplastic anemia by marrow transplantation from HLA identical siblings: prognostic factors associated with graft-versus-host disease and survival. J Clin Invest 1977: 59: 625– 632. 17 Bross DS, Tutschka PJ, Farmer ER, et al. Predictive factors for acute graft-versus-host disease in patients transplanted with HLA-identical bone marrow. Blood 1984: 63: 1265– 1270. 18 Gale RP, Bortin MM, Van Bekkum DM, et al. Risk-factors for acute graft-versus-host disease. Br J Haematol 1987: 67: 397– 406. 19 Sparkes RS, Sparkes MC, Crist M., Yale C., Mickey MR, Gale RP. MNSs antigens and graft versus host disease following bone marrow transplantation. Tissue Antigens 1980: 15: 212– 215. 20 Sullivan KM, Shulman HM, Storb R., et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981: 57: 267– 276. 21 Storb R., Prentice RL, Sullivan KM, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Int Med 1983: 98: 461– 466. 22 Ringdén O., Paulin T., Lönnqvist B., Nilsson B. An analysis of factors predisposing for chronic graft-versus-host disease. Exp Hematol 1985: 13: 1062– 1067. 23 Tsoi MS, Storb R., Dobbs S., et al. Nonspecific suppressor cells in patients with chronic graft-vs-host disease after marrow grafting. J Immunol 1979: 123: 1970– 1976. 24 Ringdén O., Witherspoon R., Storb R., Ekelund E., Thomas ED. Increased in vitro B cell IgG secretion during acute graft-versus-host disease and infection. Observations in 50 human marrow transplant recipients. Blood 1980: 55: 179– 186. 25 Atkinson K., Farewell V., Storb R., et al. Analysis of late infections after human bone marrow transplantation: Role of genotypic nonidentity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graft-versus-host disease. Blood 1982: 60: 714– 720. 26 Atkinson K., Horowitz MM, Van Bekkum DW, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990: 75: 2459– 2464. 27 Van Bekkum DW, Vos O. Treatment of secondary disease in radiation chimeras. Int J Radiat Biol 1961: 3: 173– 181. 28 Jones JM, Wilson R., Bealmear PM. Mortality and gross pathology of secondary disease in germfree mouse radiation chimeras. Radiat Res 1971: 45: 577– 588. 29 Heit H., Wilson R., Fliedner TM, Kohne E. Mortality of secondary disease in antibiotic-treated mouse radiation chimeras. In: IJ Heneghan, ed. Germfree research. New York: Academic Press, 1973: 477– 483. 30 Storb R., Prentice RL, Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. N Engl J Med 1983: 308: 302– 307. 31 Lönnqvist B., Ringdén O., Wahren B., Gahrton G., Lundgren G. Cytomegalovirus infection associated with and preceding chronic graft-versus-host disease. Transplantation 1984: 38: 465– 468. 32 Gratama JW, Zwaan FE, Stunen T., et al. Herpes-virus immunity and acute graft-versus-host disease. Lancet 1987: 1: 471– 474. 33 Boström L., Ringdén O., Sundberg B., Linde A., Tollemar J., Nilsson B. Pretransplant herpes virus serology and acute graft-versus-host disease. Transplantation 1988: 46: 548– 552. 34 Boström L., Ringdén O., Gratama JW, et al. for the Leukaemia Working Party of the European Group for Bone Marrow Transplantation. A role of herpes virus serology for the development of acute graft versus host disease. Bone Marrow Transplant 1990: 5: 321– 326. 35 Boström L., Ringdén O., Jacobsen N., Zwaan F., Nilsson B. for the Leukaemia Working Party of the European Group for Bone Marrow Transplantation. A European multicenter study of chronic graft-versus-host disease. The role of cytomegalovirus serology in recipients and donors — acute graft-versus-host disease, and splenectomy. Transplantation 1990: 49: 1100– 1105. 36 Weiden PL, Sullivan KM, Flournoy N., Storb R., Thomas ED and the Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981: 304: 1529– 1533. 37 Fefer A., Sullivan KM, Weiden P., et al. Graft versus leukemia effect in man: The relapse rate of acute leukemia is lower after allogeneic than syngeneic marrow transplantation. In: RL Truitt, RP Gale, MM Bortin, eds. Cellular Immunotherapy of Cancer. New York: A.R. Liss, 1987: pp. 401– 408. 38 Ringdén O., Horowitz MM for the Advisory Committee of the International Bone Marrow Transplant Registry. Graft-versus-leukemia reactions in humans. Transplant Proc 1989: 21: 2989– 2992. 39 Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions following bone marrow transplantation in humans. Blood 1989: 75: 555– 562. 40 Lönnqvist B., Ringdén O., Ljungman P., Wahren B., Gahrton G. Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. Br J Haematol 1986: 63: 671– 679. 41 Ringdén O., Sundberg B., Lönnqvist B., Tollemar J., Gahrton G., Nilsson B. Allogeneic bone marrow transplantation for leukemia: factors of importance for long-term survival and relapse. Bone Marrow Transplant 1988: 3: 281– 290. 42 Boström L., Ringdén O., Nilsson B., Jacobsen N., Zwaan F. for the Leukaemia Working Party of the European Group for Bone Marrow Transplantation. Early leukemia, seropositivity for several herpes viruses and chronic graft-versus-host disease are associated with decreased incidence of relapse after allogeneic bone marrow transplantation. Clin Transplant 1991: 5: 351– 358. 43 Storb R., Epstein RB, Graham TC, Thomas ED. Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 1970: 9: 240– 246. 44 Lazarus HM, Coccia PF, Herzig RH, et al. Incidence of acute graft-versus-host disease with and without methotrexate prophylaxis in allogeneic bone marrow transplant patients. Blood 1984: 64: 215– 220. 45 Sullivan KM, Storb R., Witherspoon RP, et al. Deletion of immunosuppressive prophylaxis after marrow transplantation increases hyperacute graft-versus-host disease but does not influence chronic graft-versus-host disease or relapse in patients with advanced leukemia. Clin Transplant 1989: 3: 5– 11. 46 Ringdén O. Cyclosporin in allogeneic bone marrow transplantation. Transplantation 1986: 42: 445– 452. 47 Bortin MM, Kay HEM, Gale RP, Rimm AA. Factors associated with interstitial pneumonitis after bone-marrow transplantation for acute leukaemia. Lancet 1982: 1: 437– 439. 48 Irle C., Deeg JH, Buckner CD, et al. Marrow transplantation for leukemia following fractionated total body irradiation: a comparative trial of methotrexate and cyclosporine. Leuk Res 1985: 9: 1255– 1261. 49 Bäckman L., Ringdén O., Tollemar J., Lönnqvist B. An increased risk of relapse in cyclosporin-treated compared with methotrexate-treated patients: long-term follow-up of a randomized trial. Bone Marrow Transplant 1988: 3: 463– 471. 50 Atkinson K., Dodds A., Biggs JC, Downs K., Concannon A., Ashby M. A prospective randomised trial of cyclosporin versus methotrexate after HLA-identical sibling marrow transplantation for patients with acute leukemia in first remission: analysis 2.5 years after last patient entry. Aust NZ J Med 1988: 18: 594– 599. 51 Storb R., Deeg HJ, Fisher L., et al. Cyclosporin v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 1988: 71: 293– 298. 52 Horowitz MM, Gale RP, Barrett AJ, et al. for the IBMTR. Effect of methotrexate on relapse after bone-marrow transplantation for acute lymphoblastic leukaemia. Lancet 1989: 1: 535– 537. 53 Storb R., Deeg HJ, Whitehead J., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986: 314: 729– 735. 54 Storb R., Deeg HJ, Pepe M., et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 1989: 73: 1729– 1734. 55 Ringdén O., Klaesson S., Sundberg B., Ljungman P., Lönnqvist B., Persson U. Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin as compared to monotherapy in recipients of bone marrow from donors other than HLA identical siblings. Bone Marrow Transplant 1992: 9: 19– 25. 56 Aschan J., Ringdén O., Sundberg B., Gahrton G., Ljungman P., Winiarski J. Methotrexate combined with cyclosporine A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. Bone Marrow Transplant 1991: 7: 113– 119. 57 Ringdén O., Horowitz MM, Sondel P., et al. Methotrexate, cyclosporine or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 1993: 18: 1094– 1101. 58 Aschan J., Ringdén O., Tollemar J., et al. Improved survival in marrow recipients above 30 years of age with better prevention of graft-versus-host disease. Transplant Proc 1990: 22: 195– 197. 59 Bacigalupo A., Van Lint MT, Occhini D., et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991: 77: 1423– 1428. 60 Stockschlaeder M., Storb R., Pepe M., et al. A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. Br J Haematol 1992: 80: 49– 54. 61 Forman SJ, Blume KG, Krancke RA, et al. A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: Methotrexate/Prednisone v Cyclosporine A/Prednisone. Transplant Proc 1987: 19: 2605– 2607. 62 Ringdén O., Kersey JH. Prevention and therapy of graft-versus-host disease: Report from a workshop. Bone Marrow Transplant 1992: 10 (Suppl 1): 22– 24. 63 Atkinson K., Biggs J., Concannon A., et al. A prospective randomised trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for haematological malignancy. Aust NZ J Med 1991: 21: 850– 856. 64 Ringdén O., Fauser AA. Graft-versus-host disease — prophylaxis and treatment. Bone Marrow Transplant 1993: (Suppl) (in press). 65 Kawada K., Terasaki PI. Evidence for immunosuppression by high dose gammaglobulin. Exp Haematol 1987: 15: 133– 136. 66 Sullivan KM, Kopecky KJ, Jocom J., et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990: 323: 705– 712. 67 Prentice HG, Blacklock HA, Janossy G., et al. Use of anti-T cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia. Lancet 1982: i: 700– 703. 68 Filipovich AH, Vallera DA, Youle RJ, et al. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. Transplantation 1987: 44: 62– 69. 69 Vartdal F., Kvalheim G., Lea TE, et al. Depletion of T lymphocytes from human bone marrow. Transplantation 1987: 43: 366– 371. 70 Apperly JF, Jones L., Hale G., et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplantation 1986: 1: 53– 66. 71 Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991: 78: 2120– 2130. 72 Soiffer RJ, Murray C., Mauch P., et al. Prevention of graft-versus-host disease by selective depletion of CD6–positive T lymphocytes from donor bone marrow. J Clin Oncol 1992: 10: 1191– 1200. 73 Ringdén O., Pihlstedt P., Markling L., et al. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991: 7: 221– 226. 74 Fischer A., Friedrich W., Fasth A., et al. Reduction of graft failure by a monoclonal antibody (anti-LFA-1 CD11a) after HLA nonidentical bone marrow transplantation in children with immunodeficiencies, osteopetrosis, and Fanconi's anemia: A European group for immunodeficiency/European group for bone marrow transplantation report. Blood 1991: 77: 249– 256. 75 Willemze R., Richel DJ, Falkenburg JH, et al. In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation. Bone Marrow Transplant 1992: 9: 255– 261. 76 Filipovich AH, Krawczak CL, Kersey JH, et al. Graft-versus-host disease prophylaxis with anti-T-cell monoclonal antibody OKT3, prednisone and methotrexate in allogeneic bone-marrow transplantation. Br J Haematol 1985: 60: 143– 152. 77 Ferrara J., Marion A., Murphy G., et al. Acute graft-versus-host disease: pathogenesis and prevention with a monoclonal antibody in vitro. Transplantation Proceedings 1987: 19: 2662– 2663. 78 Blaise D., Guyotat D., Reiffers J., et al. Prospective randomized study of GVHD prevention using an anti IL2 receptor (CD25) MoAb after allogeneic bone marrow transplantation (BMT). Bone Marrow Transplantation 1991: 7 (suppl 2): 150. 79 Piguet PF, Grau GE, Allet B., et al. Tumor necrosis factor/cachetin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 1987: 166: 1280– 1289. 80 Groth CG, Gahrton G., Lundgren G., et al. Successful treatment with prednisolone of graft-versus-host disease in an allogeneic bone marrow transplant recipient. Scand J Hematol 1979: 22: 333– 338. 81 Weiden PL, Doney K., Storb R., Thomas ED. Antihuman thymocyte globulin (ATG) for prophylaxis and treatment of graft-versus-host disease in recipients of allogeneic marrow grafts. Transplant Proc 1978: 10: 213– 216. 82 Gratama JW, Jansen J., Lipovich RA, Tanke HJ, Goldstein G., Zwaan FE. Treatment of acute graft-versus-host disease with monoclonal antibody OKT3. Clinical results and effect on circulating T lymphocytes. Transplantation 1984: 38: 469– 474. 83 Gluckman E., Devergie A., Varin F., et al. Treatment of steroid resistant severe acute graft versus host disease with monoclonal PAN T OKT3 antibody. Exp Hematol 1984: 12 (suppl 15): 66– 67. 84 Hymes SR, Morison WL, Farmer ER, Walters LL, Tutschka PJ, Santos GW. Methoxsalen and ultraviolet A radiation in treatment of chronic cutaneous graft-versus-host reaction. J Am Acad Dermatol 1985: 12: 30– 37. 85 Hervé P., Wijdenes J., Bergerat JP, et al. Treatment of acute graft versus host disease with monoclonal antibody to IL2 receptor. Lancet 1988: 2: 1072– 1073. 86 Vogelsang GB, Santos GW, Colvin OM, Chen T. Thalidomide for graft-versus-host disease. Lancet 1988: 1: 827. 87 Deeg HJ, Loughran JR, Storb R., et al. Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. Transplantation 1985: 40: 162– 166. 88 Martin PJ, Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment. Blood 1990: 76: 1464– 1472. 89 Martin PJ, Hansen JA, Anasetti C., et al. Treatment of acute graft-versus-host disease with anti-CD3 monoclonal antibodies. Am J Kidney Dis 1988: XI: No 2: 149– 152. 90 Remlinger K., Martin PJ, Hansen JA. Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease. Hum Immunol 1984: 9: 21– 35. 91 Hervé P., Racadot E., Wijdenes J., et al. Monoclonal anti TNF alpha antibody in the treatment of acute GVHD refractory both to corticosteroids and anti IL-2 R antibody. Bone Marrow Transplantation 1991: 7 (suppl 2): 149. 92 Anasetti C., Martin PJ, Hansen JA, et al. A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease. Transplantation 1990: 50: 49– 54. 93 Byers V., Henslee PJ, Kernan NA, et al. Use of an anti-Pan T-Iymphocyte ricin A chain immunotoxin in steroid-resistant acute graft-versus-host disease. Blood 1990: 75: 1426– 1432. 94 Atkinson K., Storb R., Ochs HD, et al. Thymus transplantation after allogeneic bone marrow graft to prevent chronic graft-versus-host disease in humans. Transplantation 1982: 33: 168– 173. 95 Witherspoon RP, Hersman J., Storb R., et al. Thymosin fraction 5 does not accelerate reconstitution in immunologic reactivity after human marrow grafting. Br J Haematol 1983: 55: 595– 608. 96 Blume KG, Beutler E., Bross KJ, et al. Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia. N Engl J Med 1980: 302: 1041– 1046. 97 Lindholm A., Zucker W., Ringdén O., Lönnqvist B. Long term cyclosporine treatment in bone marrow transplant recipients. Bone Marrow Transplantation 1986: 1 (Suppl 1): 85. 98 Sullivan KM, Witherspoon RP, Storb R., et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: Prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988: 72: 546– 554. 99 Sullivan KM, Witherspoon RP, Storb R., et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 1988: 72: 555– 561. 100 Wingard JR, Piantadosi S., Vogelsang GB, et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 1989: 74: 1428– 1435. 101 Socie G., Devergie A., Cosset JM, et al. Low-dose (one gray) total-lymphoid irradiation for extensive, drug-resistant chronic graft-versus-host disease. Transplantation 1990: 49: 657– 658. 102 Raemaekers J., De Witte T., Schattenberg A., Van Der Lely N. Prevention of leukemic relapse after transplantation with lymphocyte depleted marrow by intensification of the conditioning regimen with a 6-day continuous infusion of anthracyclines. Bone Marrow Transplant 1989: 4: 167– 171. 103 Tollemar J., Ringdén O., Tydén G. Liposomal Amphotericin-B (AmBisome) treatment in solid organ and bone marrow transplant recipients. Efficacy and safety evaluation. Clin Transplant 1990: 4: 167– 175. 104 Paulin T., Ringdén O., Ljungman P., Nilsson B. Symptomatic cytomegalovirus infection after bone marrow transplantation. Clin Transplant 1989: 3: 279– 285. 105 Zaia JA, Schmidt GM. Prophylaxis of CMV infection after BMT. Bone Marrow Transplant 1992: 10 (Suppl 1): 139– 143. 106 Starzl TE, Abu-Elmagd K., Tzakis A., Fung JJ, Porter KA, Todo S. Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs", side effects, mechanisms, and practical pharmacokinetics. Transplant Proc 1991: 23: 914– 919. 107 Morris R. Rapamycins: Antifungal, antitumor, antiproliferative and immunosuppressive macrolides. Transplant Rev 1992: 6: 39– 87. 108 Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984: 307: 168. 109 Sykes M. Dissociating graft-vs-host disease from the graft-vs-leukemia effect of allogeneic T cells: The potential role of 1L-2. Bone Marrow Transplant 1992: 10 (Suppl 1): 1– 4. Citing Literature Volume51, Issue1July 1993Pages 1-12 ReferencesRelatedInformation